Trade Abbvie - ABBV CFD

Add to favourite

164.48

View detailed chart

0.57

Low: 164.48

High: 167.56

Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

Summary
Historical Data

Trading сonditions

Spread

0.57

Long position overnight fee

-0.024151%

Short position overnight fee

0.001929%

Overnight fee time

22:00 (UTC)

Min traded quantity

0.65

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	169.57
Open	167.56
1-Year Change	21.45%
Day's Range	164.48 - 167.56

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Nov 15, 2024	164.48	-3.48	-2.07%	167.96	169.29	164.48
Nov 14, 2024	169.57	0.02	0.01%	169.55	171.51	168.47
Nov 13, 2024	170.17	-0.87	-0.51%	171.04	172.57	169.46
Nov 12, 2024	171.03	-4.73	-2.69%	175.76	176.52	170.95
Nov 11, 2024	174.35	-3.98	-2.23%	178.33	178.40	172.60
Nov 8, 2024	199.40	-1.33	-0.66%	200.73	201.70	199.06
Nov 7, 2024	200.41	-0.74	-0.37%	201.15	201.84	199.07
Nov 6, 2024	201.02	-4.21	-2.05%	205.23	205.99	200.64
Nov 5, 2024	201.48	1.33	0.66%	200.15	202.33	197.62
Nov 4, 2024	200.42	-3.31	-1.62%	203.73	203.98	199.80
Nov 1, 2024	203.47	-0.29	-0.14%	203.76	204.64	202.22
Oct 31, 2024	203.77	2.31	1.15%	201.46	207.18	200.69
Oct 30, 2024	201.31	9.96	5.21%	191.35	202.28	188.15
Oct 29, 2024	189.42	-0.27	-0.14%	189.69	190.82	188.27
Oct 28, 2024	189.61	1.64	0.87%	187.97	190.08	187.45
Oct 25, 2024	187.73	-1.41	-0.75%	189.14	189.64	187.11
Oct 24, 2024	189.57	1.51	0.80%	188.06	190.39	187.95
Oct 23, 2024	187.79	-0.44	-0.23%	188.23	189.16	187.45
Oct 22, 2024	188.61	2.63	1.41%	185.98	189.02	185.96
Oct 21, 2024	186.48	-1.73	-0.92%	188.21	189.18	185.81

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AbbVie Company profile

AbbVie Inc. is a research-based pharmaceutical company, specialising in the discovery and development of biopharmaceuticals and small molecule drugs. With a team of around 29,000 scientists, researchers, manufacturing specialists and communications professionals across the globe, the company introduces new approaches to treating chronic conditions and life-threatening health issues. In 2019, AbbVie was ranked 96th on the Fortune 500 list of America’s biggest companies. More than 30 million patients in over 170 countries are treated by AbbVie’s medicines annually.

Headquartered in North Chicago, Illinois, AbbVie has 22 primary research and manufacturing facilities around the world. The company’s research centres are in the US, Germany and Japan; and its manufacturing sites are located in the USA, Puerto Rico, Ireland, Germany, Italy and Singapore.

The company produces medicines aimed at treating autoimmune diseases, cancers, viruses (including hepatitis C and HIV), neurological and metabolic disorders. According to the Wall Street Journal, in 2016, a specialty drug ibrutinib, retailed by the company, cost from $116,600 to $155,400 a year wholesale in the US. AbbVie estimates global sales of the drug at $5 billion in 2020.

The history of AbbVie started in 2013 when Abbott Laboratories split into two publicly traded companies. One, using the old company name, was to specialise in medical equipment and devices and nutritional products; the other, AbbVie, was to be a research-driven pharmaceutical manufacturer. From the start, AbbVie was interested in acquisitions: in 2014, it acquired ImmuVen for an undisclosed amount, and in 2015, AbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers.

Presently, the AbbVie share price is listed on the New York Stock Exchange (NYSE). It is also a constituent of both the S&P 100 and 500 indices. In 2018, AbbVie reported its annual revenues of over $32.75 billion. During the same year, the ABBV stock price hit an all-time high of $123. As of July 2019, the company’s market capitalisation was set at around $106.13 billion.

Get the latest news on the Abbvie share price and stay on top of the ABBV share price chart with Capital.com.

Industry:

Pharmaceuticals (NEC)

1 N Waukegan Rd
NORTH CHICAGO
ILLINOIS 60064
US

News

Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target

Can Shiba Inu reinvent itself to become a worthy long-term investment?

08:36, 15 November 2024

Trump trades charge as Bitcoin hits $US80,000

Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.

10:48, 13 November 2024

Australian jobs data expected to point to solid labour market conditions

Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.

10:16, 13 November 2024

FOMC cuts interest rates as expected and sticks to its line on future policy

The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.

13:33, 8 November 2024

FOMC and BOE preview: further rate cuts expected

Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.

14:14, 5 November 2024

RBA meeting preview: No change to policy expected as inflation fight continues

The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.

13:35, 4 November 2024